OliX Pharmaceuticals, Inc
Research OliX Pharmaceuticals, Inc (226950.KQ) on Bullrun: market cap KRW 2.23T. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker226950.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 2.23T
- Financial periodQ2 2026
- RevenueKRW 2.62B
- Net income-KRW 10.99B
- Free cash flow-KRW 16.11B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 2.23T.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 2.23T | n/a | n/a | n/a |
Dividend history
About OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OliX Pharmaceuticals, Inc's market cap?
OliX Pharmaceuticals, Inc's market capitalization is KRW 2.23T.
What does OliX Pharmaceuticals, Inc do?
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis.